Bone mineral density in schizophrenia patients on antipsychotics;Antipsikotik ilaç kullanan şizofreni hastalarinda kemik mineral yoǧunluǧu

Klinik Psikofarmakoloji Bulteni

Volumn 19, Issue 4, 2009, Pages 402-406

  Altindaǧ, Özlem ^a   Altindaǧ, Abdurrahman ^a   Virit, Osman ^a   Savaş, Haluk A ^a   Yilmaz, Mustafa ^a   Bozgeyik, Öznur ^a   Aydeniz, Ali ^a   Gürsoy, Savaş ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Antipsychotics medication; Bone mineral density; Schizophrenia

Indexed keywords

ALKALINE PHOSPHATASE; NEUROLEPTIC AGENT; PARATHYROID HORMONE; PROLACTIN;

ADULT; AGE DISTRIBUTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MENTAL PATIENT; PARATHYROID HORMONE BLOOD LEVEL; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SIDE EFFECT; SMOKING HABIT; TREATMENT DURATION;

EID: 77952195418     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kim CJ, Oh KW, Rhee EJ, Kim KH, Jo SK, Jung CH, Won JC, Park CY, Lee WY, Park SW, et al. Relationship between body composition and bone mineral density in perimenopausal Korean women. Clin Endocrinol (Oxf). 2009;71:18-26
2. Bischoff L, Derk CT. Premenopausal osteoporosis. Minerva Med 2008; 99:55-63
3. Çetinarslan B. Sekonder Osteoporoz. Turkiye Klinikleri J Endocrin 2004; 114-122
4. O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005; 25:26-31
5. Altindag O, Altindag A, Asoglu M, Gunes M, Soran N, Deveci Z. Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int J Clin Pract 2007; 61:416-20
6. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57: 485
7. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-275
8. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Revised. NIMH publication DHEW publ NO (Adm) 76-338. Bethesda MD: National Institute of Mental Health, 1976; 217-222
9. Kostakoglu AE, Batur S, Tiryaki A. "Pozitif ve Negatif Sendrom Ölçeginin (PANSS) Türkçe Uyarlamasinin Geçerlilik ve Güvenilirliǧi". Türk Psikoloji Dergisi 1999; 14:23-32
10. Allender E, Lindahl BIB and the MEDOS Study Group; The Mediteranean Osteoporosis Study (MEDOS): Theoritical andvpractical issues of a major international porject on hip fracture epidemiology. Bone 1993; 14:37-43
11. Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ; APLUS study group. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin Neurosci 2009; 63:73-81
12. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22:1085-1096
13. Halbreich U, Rojanski N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R. Decreased bone mineral density in medicated psychiatric patients with schizophrenia: mechanism and related adverse effect. Psychoneuroendocrinology 2003; 28:53-67
14. Kurt E, Emül HM, Oral HT. Yeni antipsikotikler ve haloperidolün Prolaktin ûzerindeki etkilerinin karşilaştirilmasi. Anadolu Psikiyatri Dergisi 2008; 9:44-48
15. Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998; 83:807-813
16. Temiz ST, Erol A. Antipsikotiklere Baǧli Hiperprolaktinemi ve Osteoporoz. Bulletin of Clinical Psychopharmacology 2008; 18:62-68
17. Altinbaş K, Kurt E, Oral ET. İkinci Kuşak Antipsikotiklerin Endokrin Yan Etkileri: İstisna mi, Kural mi? Anadolu Psikiyatri Dergisi 2005; 6:259-66
18. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992; 11:851-6
19. Gür A, Denli A, Nas K, Cevik R, Karakoc M, Sarac AJ, Erdogan F. Possible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy. Rheumatol Int 2002; 22:194-8
20. Tot Ş. Osteoporozun psikiyatrik yönleri. Anadolu Psikiyatri Dergisi 2004; 5:45-49
21. Türkoǧlu A, Şengül C, Okay T, Dilbaz N. Şizofreni hastalarinda serum IL-6 ve IL-8 düzeyleri antipsikotik tedaviyle deǧişimi Klinik Psikofarmakoloji Bülteni 2007; 17:55-61